Coronavirus was initially identified in the Guangdong province of southern China in November 2002. Known by the name, severe acute respiratory syndrome coronavirus (SARS-CoV) is thought to be an animal virus that emerged from bats and became epidemic by affecting 26 countries and further resulting in more than 8,000 cases in 2003.
Browse report with detailed COVID-19 impact analysis on Coronavirus Diagnostic Kit Market Revenue Estimation and Demand Forecast
Middle East respiratory syndrome coronavirus (MERS-CoV) infection was first reported in September 2012 in Saudi Arabia. Till date, nearly 2,500 cases of this type of infection has been reported in 27 countries in a near the Arabian Peninsula. In addition, the largest outbreak of MERS-CoV outside this peninsular region occurred in the Republic of Korea in 2015.
And now, with the outbreak of pneumonia of unknown aetiology in Wuhan City, Hubei Province, China, COVID-19, also known as SARS-CoV2 has emerged as a pandemic infection, as declared by the World Health Organization (WHO).
The 2019-novel coronavirus (2019-nCoV) real-time reverse transcription (RT) PCR diagnostic panel, provided by the Centers for Disease Control and Prevention (CDC) in the U.S., is a test intended for the qualitative detection of nucleic acid from the 2019-nCoV in upper and lower respiratory specimens such as nasopharyngeal or oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) collected from individuals who meet 2019-nCoV clinical and/or epidemiological criteria. The criteria include clinical signs and symptoms associated with 2019-nCoV infection, contact with a probable or confirmed 2019-CoV case, and history of travel to geographic locations where positive cases have been detected.
Furthermore, in India, on March 24th, 2020, a Pune-based molecular diagnostic company, MylabLifesolutions Pvt. Ltd., became the first Indian company to granted validation for its COVID-19 diagnostic test kits, or RT-PCR, by the Drug Controller of India, after the validation from the National Institute of Virology. With the rapid increase in the total number of COVID-19 cases, across the globe, the need for rapid and reliable diagnostics are increasing, thereby, boosting the demand for coronavirus diagnostic kits, significantly.